- Home
- IMCC vs SLXN Comparison
IMCC vs SLXN Comparison
Compare IMCC & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- SLXN
- Stock Information
- Founded
- IMCC 1980
- SLXN 2008
- Country
- IMCC Israel
- SLXN Israel
- Employees
- IMCC N/A
- SLXN N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- SLXN
- Sector
- IMCC Health Care
- SLXN
- Exchange
- IMCC Nasdaq
- SLXN NYSE
- Market Cap
- IMCC 12.0M
- SLXN 7.3M
- IPO Year
- IMCC N/A
- SLXN N/A
- Fundamental
- Price
- IMCC $3.07
- SLXN $0.76
- Analyst Decision
- IMCC
- SLXN Strong Buy
- Analyst Count
- IMCC 0
- SLXN 1
- Target Price
- IMCC N/A
- SLXN $5.00
- AVG Volume (30 Days)
- IMCC 155.5K
- SLXN 715.8K
- Earning Date
- IMCC 08-13-2025
- SLXN 08-21-2025
- Dividend Yield
- IMCC N/A
- SLXN N/A
- EPS Growth
- IMCC N/A
- SLXN N/A
- EPS
- IMCC N/A
- SLXN N/A
- Revenue
- IMCC $37,894,737.00
- SLXN N/A
- Revenue This Year
- IMCC $47.12
- SLXN N/A
- Revenue Next Year
- IMCC $12.83
- SLXN N/A
- P/E Ratio
- IMCC N/A
- SLXN N/A
- Revenue Growth
- IMCC 12.68
- SLXN N/A
- 52 Week Low
- IMCC $1.29
- SLXN $0.58
- 52 Week High
- IMCC $7.12
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- IMCC 58.57
- SLXN N/A
- Support Level
- IMCC $2.76
- SLXN N/A
- Resistance Level
- IMCC $3.75
- SLXN N/A
- Average True Range (ATR)
- IMCC 0.35
- SLXN 0.00
- MACD
- IMCC 0.04
- SLXN 0.00
- Stochastic Oscillator
- IMCC 78.69
- SLXN 0.00
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.